BioCentury
ARTICLE | Tools & Techniques

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

Led by CEO Tak, Flagship Pioneering’s Kintai adds preclinical validation to its platform with obesity data

January 23, 2020 10:08 PM UTC
Updated on Jan 28, 2020 at 7:36 PM UTC

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s links to human pathology without touching the bacteria.

Kintai Therapeutics Inc., which emerged from Flagship Pioneering last year, named KTX-0200 as its lead compound and said it helped treat obesity and other features of metabolic syndrome in rodent models. ...

BCIQ Company Profiles

Kintai Therapeutics Inc.